<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00044694</url>
  </required_header>
  <id_info>
    <org_study_id>2993-116</org_study_id>
    <nct_id>NCT00044694</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Short-Term, Dose-Response Study to Examine the Effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, blinded, placebo-controlled, short-term, dose-response
      study to examine the effects on glucose control of AC2993 as compared to placebo in patients
      with type 2 diabetes. Patients will be individuals with type 2 diabetes treated with
      metformin for at least 3 months prior to screening. Patients whose diabetes management
      consists of diet and exercise will also be eligible for this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">May 2003</completion_date>
  <primary_completion_date type="Actual">May 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28</measure>
    <time_frame>Baseline (Day 1) to Day 28</time_frame>
    <description>Change in HbA1c from Baseline (Day 1) to study termination (Day 28)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c from Baseline to Day 14</measure>
    <time_frame>Baseline, Day 14</time_frame>
    <description>Change in HbA1c from Baseline (Day 1) to Day 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting plasma glucose from Baseline to Day 14 and to Day 28</measure>
    <time_frame>Baseline, Day 14, Day28</time_frame>
    <description>Change in fasting plasma glucose from Baseline (Day 1) to Day 14 and to study termination (Day 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum fructosamine from Baseline (Day 1) to Day 14 and to Day 28</measure>
    <time_frame>Baseline, Day 14, Day 28</time_frame>
    <description>Change in serum fructosamine from baseline (Day 1) to Visit 4 (Day 14) and to study termination (Day 28)</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Placebo 0.01 mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 week placebo lead-in followed by Placebo 0.01 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.02 mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 week placebo lead-in followed by Placebo 0.02 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.03 mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 week placebo lead-in followed by Placebo 0.03 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 0.04 mL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 week placebo lead-in followed by Placebo 0.04 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC2993 2.5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 week placebo lead-in (0.01 mL) followed by AC2993 2.5 mcg; 0.01 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC2993 5.0 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 week placebo lead-in followed by AC2993 5.0 mcg; 0.01 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC2993 7.5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 week placebo lead-in followed by AC2993 7.5 mcg; 0.03 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AC2993 10.0 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 week placebo lead-in period followed by AC2993 10.0 mcg; 0.04 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.01 mL</intervention_name>
    <description>2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily</description>
    <arm_group_label>Placebo 0.01 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.02 mL</intervention_name>
    <description>2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily</description>
    <arm_group_label>Placebo 0.02 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.03 mL</intervention_name>
    <description>2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily</description>
    <arm_group_label>Placebo 0.03 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 0.04 mL</intervention_name>
    <description>2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily</description>
    <arm_group_label>Placebo 0.04 mL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC2993 2.5 mcg</intervention_name>
    <description>2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily</description>
    <arm_group_label>AC2993 2.5 mcg</arm_group_label>
    <other_name>synthetic exendin-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC2993 5.0 mcg</intervention_name>
    <description>2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily</description>
    <arm_group_label>AC2993 5.0 mcg</arm_group_label>
    <other_name>synthetic exendin-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC2993 7.5 mcg</intervention_name>
    <description>2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily</description>
    <arm_group_label>AC2993 7.5 mcg</arm_group_label>
    <other_name>synthetic exendin-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AC2993 10.0 mcg</intervention_name>
    <description>2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily</description>
    <arm_group_label>AC2993 10.0 mcg</arm_group_label>
    <other_name>synthetic exendin-4</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with type 2 diabetes

          -  Treated with diet and exercise alone or with metformin for at least 3 months prior to
             screening

          -  BMI 27-45 kg/m^2

          -  HbA1c between 7.0 % and 8.0 %

        Exclusion Criteria:

          -  Treated with other oral anti-diabetic agents other than metformin within 3 months of
             screening

          -  Patients previously treated with AC2993

          -  Patients presently treated with insulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Innovative Clinical Trials</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthsouth Clinical Research</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology Clinic of O.C.</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Medical Group</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>90706</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research Network</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bautista Research and Medical Clinic</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whittier Institute for Diabetes</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Richard Cherlin, M.D.</name>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <zip>95032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Martinez Medical Clinic</name>
      <address>
        <city>Moreno Valley</city>
        <state>California</state>
        <zip>92553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anshutz Outpatient Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Clinic</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research-Gainsville</name>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research-Pinellas Park</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Group of North Georgia</name>
      <address>
        <city>Blairsville</city>
        <state>Georgia</state>
        <zip>30512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-West Medical Research Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research-Honolulu</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research-Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedar-Crosse Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northshore Medical Research, LLC</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Institute</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70458</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Melvin Kramer, MD</name>
      <address>
        <city>Concord</city>
        <state>Massachusetts</state>
        <zip>01742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research-Edina</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mississippi Medical Research, LLC</name>
      <address>
        <city>Gulfport</city>
        <state>Mississippi</state>
        <zip>39501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Health Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Advanced Research</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fallen Timbers Internal Medicine, LLC</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Millenium Research</name>
      <address>
        <city>Benbrook</city>
        <state>Texas</state>
        <zip>76126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthsouth Clinical Research</name>
      <address>
        <city>Desoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/Clinical Studies Unit</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Center of the Southwest</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Diabetes Center at the University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2002</study_first_submitted>
  <study_first_submitted_qc>September 4, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2002</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

